Emerging Antibiotic Resistance, Medical and Molecular Microbiology Unit, Department of Medicine, University of Fribourg, Fribourg, Switzerland; INSERM European Unit (IAME, France), University of Fribourg, Fribourg, Switzerland.
Emerging Antibiotic Resistance, Medical and Molecular Microbiology Unit, Department of Medicine, University of Fribourg, Fribourg, Switzerland; INSERM European Unit (IAME, France), University of Fribourg, Fribourg, Switzerland; Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), Fribourg, Switzerland.
Clin Microbiol Infect. 2017 Sep;23(9):676.e1-676.e5. doi: 10.1016/j.cmi.2017.03.015. Epub 2017 Mar 23.
To evaluate whether acquired resistance to cationic antimicrobial peptide (CAMP) group molecules, being normal components of the human immune system, may select co-resistance to antibiotic peptides such as polymyxins, considering they share the same mechanism of action. We aimed to evaluate strains producing the recently identified plasmid-encoded polymyxin resistance determinant MCR-1, which is a phosphoethanolamine transferase that modifies the lipopolysaccharide structure of Gram-negative bacteria.
In vitro susceptibility studies were performed using human CAMPs, namely cathelicidin LL-37, α-defensin 5 (HD5), and β-defensin 3 (HDB3), towards MCR-1-producing and colistin-resistant Escherichia coli or Klebsiella pneumoniae.
Cross-resistance to CAMPs and colistin mediated by MCR-1 or chromosomal mechanisms was neither observed in E. coli nor in K. pneumoniae.
Future therapeutic development of human CAMPs is not likely to be impeded by the spread of MCR-1 plasmid-mediated resistance to polymyxins, at least in E. coli.
评估阳离子抗菌肽 (CAMP) 组分子(人体免疫系统的正常组成部分)获得性耐药是否可能选择对多黏菌素等抗生素肽产生共同耐药性,因为它们具有相同的作用机制。我们旨在评估产生最近鉴定的质粒编码多黏菌素耐药决定因子 MCR-1 的菌株,该因子是一种磷酸乙醇胺转移酶,修饰革兰氏阴性菌的脂多糖结构。
使用人 CAMP,即抗菌肽 LL-37、α-防御素 5 (HD5) 和 β-防御素 3 (HDB3),对产 MCR-1 和多黏菌素耐药的大肠杆菌或肺炎克雷伯菌进行体外药敏研究。
MCR-1 或染色体机制介导的 CAMP 和多黏菌素的交叉耐药性在大肠杆菌和肺炎克雷伯菌中均未观察到。
至少在大肠杆菌中,MCR-1 质粒介导的多黏菌素耐药性的传播不太可能阻碍人 CAMP 的未来治疗开发。